Terapi Antiangina untuk Angina Pektoris Stabil
DOI:
https://doi.org/10.55175/cdk.v49i12.330Keywords:
angina pektoris stabil, antiangina, ivabradine, nicorandil, ranolazine, trimetazidineAbstract
Penggunaan antiangina profilaksis pada penderita angina pektoris stabil bertujuan untuk meredakan gejala angina dan mengurangi frekuensi gejala angina. Beta-blocker (BB), Calcium Channel Blocker (CCB), dan nitrat merupakan tiga golongan antiangina tradisional yang telah lama digunakan untuk terapi antiangina. Telaah ilmiah berbasis bukti telah menunjukkan manfaat penggunaan antiangina lini kedua termasuk ivabradine, nicorandil, ranolazine, dan trimetazidine. Obat-obatan tersebut menjadi pilihan baru yang berpotensi meningkatkan kualitas hidup penderita angina pektoris stabil Prophylaxis antianginal agents for patients with stable angina pectoris is needed for angina symptom control and to reduce angina attacks. Beta-blocker (BB), Calcium Channel Blocker (CCB), and nitrates are the three traditional antianginals commonly used as antianginal agents. Evidence-based studies have shown the benefits of second-line antianginal agents including ivabradine, nicorandil, ranolazine, and trimetazidine. These novel agents could become part of the treatment to improve the quality of life of stable angina pectoris patients.
Downloads
References
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Laporan Nasional Riskesdas 2018. Jakarta: LP Balitbangkes Kemenkes RI; 2019.
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Riset kesehatan dasar 2013. Jakarta: LP Balitbangkes Kemenkes RI; 2013.
Uli RE, Satyana RPU, Zomer E, Magliano D, Liew D, Ademi Z. Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. BMJ Open. 2020; 10: e039221.
P2PTM Kemenkes RI. Apa definisi penyakit jantung koroner? [Internet]. [cited 2022 Jun 3]; Available from: http://p2ptm.kemkes.go.id/infographic/apa-definisi-penyakit-jantung-koroner-pjk
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41: 407-77
Berry C. Stable coronary syndromes: the case for consolidating the nomenclature of stable ischemic heart disease. Circulation. 2017; 136: 437-9.
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman tatalaksana sindrom koroner akut. Edisi ke-4; Jakarta: Perki; 2018.
Gallucci G, Tartarone A, Lerose R, Lalinga AV, Capobianco AM. Cardiovascular risk of smoking and benefits of smoking cessation. J Thorac Dis. 2020; 12 :386-76.
Threapleton DE, Greenwood DC, Evans CEL, Cleghorn CL, Nykjaer C, Woodhead C, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013; 347: 1-12.
Powell-Wiley TM, Poirier P, Burke LE, Despres J, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021; 143: e984-1010.
Rousan TA, Thadani U. Stable angina medical therapy management guidelines: a critical review of guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. Eur Cardiol. 2019; 14: 18-22.
National Institute for Health and Care Excellence. Stable angina: management. London: NICE; 2011.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation. 2012; 126: e354-471.
Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005; 97. 618-28.
Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011; 123. 2132-44.
Giannopoulos AA, Giannoglou GD, Chatzizisis YS. Pharmacological approaches of refractory angina. Pharmacology & Therapeutics. 2016; 163: 118-31.
Meritxell S, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study. Pharmacol Res. 2019; 139-106-12.
Arnim T, Duck H, Morgenstern HO, Teichmann W, Wely RL, Sagastagoitia D, et al. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. JACC. 1995; 25: 231-8.
Alahamd Y, Swehli HAI, Rahhal A, Sardar S, Elhassan MAM, Alsamel S, Ibrahim OA. Calcium Channel Blockers. In: Ambrosi PB, Ahmad R, Abdullahi A, Agrawal A, editors. New Insight into Cerebrovascular Diseases - An Updated Comprehensive Review [Internet]. London: IntechOpen; 2020 [cited 2022 Apr 19].
De Rosa ML, Giordano A, Melfi M, Guardia DD, Ciaburri F, Rengo F. Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pektoris. Int J Cardiol. 1998; 63: 27-35.
Bassan MM, Weiler-Ravell D, Shalev O. Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiveing propranolol: a double-blind study. Circulation. 1983; 68: 568-75.
Munzel T, Daiber A, Gori T. More answers to the still unresolved question of nitrate tolerance. Eur Heart J. 2013; 34: 2666-73.
Reed M, Kerndt CC, Nicolas D. Ivabradine. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507783/
Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376: 875-85.
Fox K, Ford I, Steg PG, Tardif J, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371: 1091-99.
Corlanor [Product information]. USA: Amgen; 2019.
Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pektoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007; 67: 393-405.
Tardif J, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur H J. 2005; 26: 2529-36.
Cheng K, Alhumood K, Shaer FE, Silva R. The role of nicorandil in the management of chronic coronary syndromes in the Gulf region. Adv Ther. 38: 925-48.
Lesnefsky EJ. The IONA study: preparing the myocardium for ischaemia? Lancet. 2002;359(9314): 1262–3.
Zhu WL, Shan YD, Guo JX, Wei JP, Yang XC, Li TD, et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pektoris in China. Circ J. 2007;71(6):826–33.
Meeter K, Kelder JC, Tijssen JG, Bucx JJ, Henneman JA, Kerker JP, et al. Efficacy of nicorandil versus propranolol in mild stable angina pektoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol. 1992;20(Suppl 3): S59–66.
SWAN Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pektoris: the SWAN study. J Clin Basic Cardiol. 1999; 2: 213–7.
Tamargo J, Amoros I, Barana A, Caballero R, Delpon E. New investigational drugs for the management of acute heart failure syndromes. Current Med Chem. 2010; 17: 1-28.
Chaitman BR, Skettino SL, Parker JK, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. JACC. 2004; 1375-82.
Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291: 309-16.
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky A, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA. 2007; 297: 1775-83.
Gutierrez JA, Karwatowska-Prokoczuk E, Murphy SA, Belardinelli L, Farzaneh-Far R, Walker G, et al. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 Trial. Clin Cardiol. 2015; 38; 469-75.
Dalal JJ, Mishra S. Modulation of myocardial energetics: an important category of agents in the multimodal treatment of coronary artery disease and heart failure. Indian H J. 2017; 69: 393-401.
Derty JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P, et al. Trimetazidine: a new concept in the treatment of angina. Br J Clin Pharmac. 1994; 37: 279-88.
Koylan N, Bilge AK, Adalet K, Mercanoglu F, Buyukozturk K. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiologica. 2004; 59: 644-50.
Chazov EI, Lepakchin VK, Zharova EA, Fitilev SB, Levin AM, Rumiantzeva EG, et al. Trimetazidine in angina combination therap – the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 12; 2005: 35-42.
Iyengar SS, Rosano GMC. Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). AM J Cardiovasc Drugs. 2009; 9: 293-7.
Tolunay H. Antinociceptive effect of ranolazine and trimetazidine. Expert Rev Cardiovasc Ther. 2021; 19(5): 457-64.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
